{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:24:29Z","timestamp":1786991069981,"version":"build-2736575974"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.intimp.2024.112043","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T22:37:42Z","timestamp":1715380662000},"page":"112043","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Current status of bispecific antibodies and CAR-T therapies in multiple myeloma"],"prefix":"10.1016","volume":"134","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5477-5771","authenticated-orcid":false,"given":"Wojciech","family":"Szlasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Dybko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/asheducation-2014.1.1","article-title":"Multiple myeloma: a model for scientific and clinical progress","volume":"2014","author":"Miguel","year":"2014","journal-title":"Hematology"},{"issue":"12","key":"10.1016\/j.intimp.2024.112043_b0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1159\/000520312","article-title":"Multiple myeloma: molecular pathogenesis and disease evolution","volume":"44","author":"Heider","year":"2021","journal-title":"Oncol Res Treat"},{"issue":"5","key":"10.1016\/j.intimp.2024.112043_b0015","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/mp.55.5.273","article-title":"Molecular aspects of multiple myeloma","volume":"55","author":"Pratt","year":"2002","journal-title":"Mol. Pathol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2003-04-1045","article-title":"Treatment of multiple myeloma","volume":"103","author":"Barlogie","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2024.112043_b0025","doi-asserted-by":"crossref","unstructured":"B. E. Monteith, I. Sandhu, and A. S. Lee, \u201cManagement of Multiple Myeloma: A Review for General Practitioners in Oncology,\u201d Current Oncology 2023, Vol. 30, Pages 4382-4401, vol. 30, no. 5, pp. 4382\u20134401, Apr. 2023, doi: 10.3390\/CURRONCOL30050334.","DOI":"10.3390\/curroncol30050334"},{"issue":"12","key":"10.1016\/j.intimp.2024.112043_b0030","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1002\/ajh.25963","article-title":"Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: efficacy in transplant-ineligible untreated myeloma","volume":"95","author":"Durie","year":"2020","journal-title":"Am. J. Hematol."},{"issue":"14","key":"10.1016\/j.intimp.2024.112043_b0035","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.intimp.2024.112043_b0040","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","article-title":"Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors","volume":"186","author":"de Weers","year":"2011","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2024.112043_b0045","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1080\/14712598.2016.1221920","article-title":"Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma","volume":"16","author":"Lonial","year":"2016","journal-title":"Expert Opin. Biol. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2024.112043_b0050","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/2040620716657993","article-title":"Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab","volume":"7","author":"Einsele","year":"2016","journal-title":"Ther. Adv. Hematol."},{"issue":"10218","key":"10.1016\/j.intimp.2024.112043_b0055","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.intimp.2024.112043_b0060","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/bjh.14787","article-title":"Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth","volume":"178","author":"Dimopoulos","year":"2017","journal-title":"Br. J. Haematol."},{"issue":"23","key":"10.1016\/j.intimp.2024.112043_b0065","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0070","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol."},{"issue":"8","key":"10.1016\/j.intimp.2024.112043_b0075","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and Refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.112043_b0080","doi-asserted-by":"crossref","unstructured":"Y. Lin et al., \u201cCARTITUDE-1 final results: Phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma.,\u201d https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.8009, vol. 41, no. 16_suppl, pp. 8009\u20138009, May 2023, doi: 10.1200\/JCO.2023.41.16_SUPPL.8009.","DOI":"10.1200\/JCO.2023.41.16_suppl.8009"},{"issue":"24","key":"10.1016\/j.intimp.2024.112043_b0085","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.intimp.2024.112043_b0090","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or Refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.intimp.2024.112043_b0095","doi-asserted-by":"crossref","first-page":"Dec","DOI":"10.3390\/cancers13236067","article-title":"T cell engaging immunotherapies, highlighting Chimeric antigen receptor (CAR) T cell therapy","volume":"13","author":"De Bousser","year":"2021","journal-title":"Cancers (basel)"},{"key":"10.1016\/j.intimp.2024.112043_b0100","doi-asserted-by":"crossref","unstructured":"\u201cBiTE Therapy Active in Multiple Myeloma,\u201d Cancer Discov, vol. 9, no. 2, pp. 157\u2013158, Feb. 2019, doi: 10.1158\/2159-8290.CD-NB2019-001\/335750\/P\/BITE-THERAPY-ACTIVE-IN-MULTIPLE-MYELOMABITE.","DOI":"10.1158\/2159-8290.CD-NB2019-001"},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0105","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1182\/hematology.2019000068","article-title":"Myeloma: next generation immunotherapy","volume":"2019","author":"Cohen","year":"2019","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0110","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1182\/hematology.2023000433","article-title":"Current use of bispecific antibodies to treat multiple myeloma","volume":"2023","author":"Lee","year":"2023","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0115","first-page":"28","article-title":"BCMA-targeting approaches for treatment of multiple myeloma","volume":"63","author":"Yunxin","year":"2021","journal-title":"Panminerva Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0120","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1182\/hematology.2023000434","article-title":"Current use of CAR T cells to treat multiple myeloma","volume":"2023","author":"Firestone","year":"2023","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0125","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1182\/hematology.2020000111","article-title":"Future of CAR T cells in multiple myeloma","volume":"2020","author":"Wudhikarn","year":"2020","journal-title":"Hematology"},{"key":"10.1016\/j.intimp.2024.112043_b0130","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/6934183","article-title":"Insights on genomic and Molecular alterations in multiple myeloma and their incorporation towards risk-Adapted treatment strategy: Concise clinical review","volume":"2017","author":"Nishihori","year":"2017","journal-title":"Int J Genomics"},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0135","first-page":"9","article-title":"Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities","volume":"125","author":"Guman","year":"2024","journal-title":"Bratisl. Lek. Listy"},{"issue":"2","key":"10.1016\/j.intimp.2024.112043_b0140","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CCO.0000000000000615","article-title":"The microenvironment in myeloma","volume":"32","author":"Lomas","year":"2020","journal-title":"Curr. Opin. Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2024.112043_b0145","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1080\/09674845.2013.11669945","article-title":"Multiple myeloma: the bone marrow microenvironment and its relation to treatment","volume":"70","author":"Andrews","year":"2013","journal-title":"Br. J. Biomed. Sci."},{"issue":"11","key":"10.1016\/j.intimp.2024.112043_b0150","doi-asserted-by":"crossref","first-page":"Nov","DOI":"10.1371\/journal.pmed.1003323","article-title":"Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: a cohort study of patients in the total therapy clinical trials","volume":"17","author":"Danziger","year":"2020","journal-title":"PLoS Med."},{"issue":"2","key":"10.1016\/j.intimp.2024.112043_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garc\u00eda-Ortiz","year":"2021","journal-title":"Cancers (basel)"},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0160","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.intimp.2024.112043_b0165","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-023-00140-7","article-title":"The next-generation CAR-T therapy landscape","author":"Verma","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0170","first-page":"43","article-title":"CAR-T cells in multiple myeloma: current status","volume":"13","author":"Steiner","year":"2020","journal-title":"Memo - Magazine Eur. Med. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0175","first-page":"1","article-title":"Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting","volume":"12","author":"Hou","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2024.112043_b0180","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-143045","article-title":"Safety and adverse reactions of CAR T therapy for the treatment of multiple myeloma: a systematic review","volume":"136","author":"Javed","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2024.112043_b0185","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","article-title":"CAR-T cell therapy: the efficacy and toxicity balance","volume":"18","author":"Chohan","year":"2023","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"5","key":"10.1016\/j.intimp.2024.112043_b0190","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific antibodies in multiple myeloma: present and future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"13","key":"10.1016\/j.intimp.2024.112043_b0195","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1080\/10428194.2022.2113532","article-title":"T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape","volume":"63","author":"Kazandjian","year":"2022","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0200","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1182\/hematology.2022000334","article-title":"Antibodies and bispecifics for multiple myeloma: effective effector therapy","volume":"2022","author":"Cipkar","year":"2022","journal-title":"Hematology"},{"issue":"8","key":"10.1016\/j.intimp.2024.112043_b0205","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2024.112043_b0210","doi-asserted-by":"crossref","unstructured":"Z. Tian, M. Liu, Y. Zhang, and X. Wang, \u201cBispecific T cell engagers: an emerging therapy for management of hematologic malignancies,\u201d Journal of Hematology & Oncology 2021 14:1, vol. 14, no. 1, pp. 1\u201318, May 2021, doi: 10.1186\/S13045-021-01084-4.","DOI":"10.1186\/s13045-021-01084-4"},{"issue":"2","key":"10.1016\/j.intimp.2024.112043_b0215","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","article-title":"Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.intimp.2024.112043_b0220","unstructured":"P. Sonneveld, \u201cPhase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial.\u201d ASH, Dec. 12, 2023."},{"key":"10.1016\/j.intimp.2024.112043_b0225","doi-asserted-by":"crossref","first-page":"1101495","DOI":"10.3389\/fimmu.2023.1101495","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112043_b0230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Sterner Sterner Blood Cancer J."},{"key":"10.1016\/j.intimp.2024.112043_b0235","doi-asserted-by":"crossref","first-page":"102240","DOI":"10.1016\/j.ctrv.2021.102240","article-title":"The promise of bispecific antibodies: clinical applications and challenges","volume":"99","author":"Lim","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.intimp.2024.112043_b0240","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/bs.ircmb.2022.05.001","article-title":"Opportunities and challenges of bi-specific antibodies","volume":"369","author":"Segu\u00e9s","year":"2022","journal-title":"Int. Rev. Cell Mol. Biol."},{"issue":"2","key":"10.1016\/j.intimp.2024.112043_b0245","first-page":"73","article-title":"Current trends and challenges in the downstream purification of bispecific antibodies","volume":"4","author":"Chen","year":"2021","journal-title":"Antib Ther"},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2024.112043_b0250","doi-asserted-by":"crossref","first-page":"7379","DOI":"10.1182\/blood-2022-165339","article-title":"CD84: a novel Target for CAR T-cell therapy for acute myeloid leukemia","volume":"140","author":"P\u00e9rez-Amill","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01396-z","article-title":"BCMA-targeted CAR-T cell therapies in relapsed and\/or refractory multiple myeloma: latest updates from 2023 ASCO annual meeting","volume":"16","author":"Wu","year":"2023","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.intimp.2024.112043_b0265","doi-asserted-by":"crossref","unstructured":"Q. Lin, J. Zhao, Y. Song, and D. Liu, \u201cRecent updates on CAR T clinical trials for multiple myeloma,\u201d Molecular Cancer 2019 18:1, vol. 18, no. 1, pp. 1\u201311, Nov. 2019, doi: 10.1186\/S12943-019-1092-1.","DOI":"10.1186\/s12943-019-1092-1"},{"key":"10.1016\/j.intimp.2024.112043_b0270","doi-asserted-by":"crossref","unstructured":"J. L. Reguera-Ortega, E. Garc\u00eda-Guerrero, J. Antonio P\u00e9rez-Sim\u00f3n, and L. Garderet, \u201cCurrent Status of CAR-T Cell Therapy in Multiple Myeloma,\u201d Hemato 2021, Vol. 2, Pages 660-671, vol. 2, no. 4, pp. 660\u2013671, Oct. 2021, doi: 10.3390\/HEMATO2040043.","DOI":"10.3390\/hemato2040043"},{"key":"10.1016\/j.intimp.2024.112043_b0275","doi-asserted-by":"crossref","unstructured":"M. J. Glenn et al., \u201cElevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees,\u201d Blood Cancer Journal 2019 9:3, vol. 9, no. 3, pp. 1\u20139, Feb. 2019, doi: 10.1038\/s41408-019-0186-8.","DOI":"10.1038\/s41408-019-0186-8"},{"key":"10.1016\/j.intimp.2024.112043_b0280","doi-asserted-by":"crossref","first-page":"1050522","DOI":"10.3389\/fimmu.2022.1050522","article-title":"Chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112043_b0285","doi-asserted-by":"crossref","unstructured":"A. Heczey et al., \u201cAnti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis,\u201d Nature Medicine 2020 26:11, vol. 26, no. 11, pp. 1686\u20131690, Oct. 2020, doi: 10.1038\/s41591-020-1074-2.","DOI":"10.1038\/s41591-020-1074-2"},{"key":"10.1016\/j.intimp.2024.112043_b0290","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.693016","article-title":"CAR-T cell therapy: mechanism, Management, and mitigation of inflammatory toxicities","volume":"12","author":"Fischer","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112043_b0295","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell-associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112043_b0300","doi-asserted-by":"crossref","unstructured":"S. Depil, P. Duchateau, S. A. Grupp, G. Mufti, and L. Poirot, \u201c\u2018Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges,\u201d Nature Reviews Drug Discovery 2020 19:3, vol. 19, no. 3, pp. 185\u2013199, Jan. 2020, doi: 10.1038\/s41573-019-0051-2.","DOI":"10.1038\/s41573-019-0051-2"},{"issue":"26","key":"10.1016\/j.intimp.2024.112043_b0305","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.2021014611","article-title":"T-cell-redirecting bispecific antibodies in multiple myeloma: a revolution?","volume":"139","author":"Moreau","year":"2022","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0310","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1182\/hematology.2020000110","article-title":"Bispecifics, trispecifics, and other novel immune treatments in myeloma","volume":"2020","author":"Lancman","year":"2020","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.intimp.2024.112043_b0315","doi-asserted-by":"crossref","unstructured":"S. F. Cho, K. C. Anderson, and Y. T. Tai, \u201cTargeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy,\u201d Front Immunol, vol. 9, no. AUG, Aug. 2018, doi: 10.3389\/FIMMU.2018.01821.","DOI":"10.3389\/fimmu.2018.01821"},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0320","doi-asserted-by":"crossref","first-page":"Dec","DOI":"10.1186\/s13045-021-01170-7","article-title":"A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112043_b0325","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.2022017848","article-title":"Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy","volume":"141","author":"Van Oekelen","year":"2023","journal-title":"Blood"},{"issue":"10297","key":"10.1016\/j.intimp.2024.112043_b0330","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.intimp.2024.112043_b0335","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in Refractory Large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2024.112043_b0340","doi-asserted-by":"crossref","first-page":"1032775","DOI":"10.3389\/fonc.2022.1032775","article-title":"Bispecific antibodies in multiple myeloma treatment: a journey in progress","volume":"12","author":"Cho","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2024.112043_b0345","doi-asserted-by":"crossref","unstructured":"L. Mikkilineni and J. N. Kochenderfer, \u201cCAR T cell therapies for patients with multiple myeloma,\u201d Nature Reviews Clinical Oncology 2020 18:2, vol. 18, no. 2, pp. 71\u201384, Sep. 2020, doi: 10.1038\/s41571-020-0427-6.","DOI":"10.1038\/s41571-020-0427-6"},{"key":"10.1016\/j.intimp.2024.112043_b0350","doi-asserted-by":"crossref","unstructured":"K. Kriegsmann et al., \u201cCell-based immunotherapy approaches for multiple myeloma,\u201d British Journal of Cancer 2018 120:1, vol. 120, no. 1, pp. 38\u201344, Dec. 2018, doi: 10.1038\/s41416-018-0346-9.","DOI":"10.1038\/s41416-018-0346-9"},{"issue":"22","key":"10.1016\/j.intimp.2024.112043_b0355","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/blood.2019004176","article-title":"What is the future of immunotherapy in multiple myeloma?","volume":"136","author":"Rasche","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2024.112043_b0360","doi-asserted-by":"crossref","unstructured":"R. C. Sterner and R. M. Sterner, \u201cCAR-T cell therapy: current limitations and potential strategies,\u201d Blood Cancer Journal 2021 11:4, vol. 11, no. 4, pp. 1\u201311, Apr. 2021, doi: 10.1038\/s41408-021-00459-7.","DOI":"10.1038\/s41408-021-00459-7"},{"issue":"Supplement 1","key":"10.1016\/j.intimp.2024.112043_b0365","doi-asserted-by":"crossref","first-page":"4828","DOI":"10.1182\/blood-2021-146283","article-title":"Feasibility of outpatient CAR T cell therapy: Experience of a single institution","volume":"138","author":"Shao","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2024.112043_b0370","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.693016","article-title":"CAR-T cell therapy: mechanism, Management, and mitigation of inflammatory toxicities","volume":"12","author":"Fischer","year":"2021","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0375","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1182\/hematology.2022000396","article-title":"Cellular therapy for multiple myeloma: what\u2019s now and what\u2019s next","volume":"2022","author":"Rodriguez-Otero","year":"2022","journal-title":"Hematology"},{"issue":"4","key":"10.1016\/j.intimp.2024.112043_b0380","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1182\/bloodadvances.2020004017","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients","volume":"5","author":"Mohyuddin","year":"2021","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.intimp.2024.112043_b0385","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40261-021-01012-x","article-title":"Comparative effectiveness Research for CAR-T therapies in multiple myeloma: appropriate Comparisons require Careful considerations of data sources and patient populations","volume":"41","author":"Shah","year":"2021","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.intimp.2024.112043_b0390","article-title":"Correlation of cytokine release syndrome with prognosis after Chimeric antigen receptor T cell therapy: analysis of 54 patients with relapsed or Refractory multiple myeloma","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112043_b0395","doi-asserted-by":"crossref","unstructured":"O. Van Oekelen et al., \u201cNeurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy,\u201d Nature Medicine 2021 27:12, vol. 27, no. 12, pp. 2099\u20132103, Dec. 2021, doi: 10.1038\/s41591-021-01564-7.","DOI":"10.1038\/s41591-021-01564-7"},{"key":"10.1016\/j.intimp.2024.112043_b0400","doi-asserted-by":"crossref","unstructured":"Y. Zhang, D. Qin, A. C. Shou, Y. Liu, Y. Wang, and L. Zhou, \u201cExploring CAR-T Cell Therapy Side Effects: Mechanisms and Management Strategies,\u201d Journal of Clinical Medicine 2023, Vol. 12, Page 6124, vol. 12, no. 19, p. 6124, Sep. 2023, doi: 10.3390\/JCM12196124.","DOI":"10.3390\/jcm12196124"},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0405","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-021-09102-x","article-title":"Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and meta-analysis","volume":"22","author":"Luo","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0410","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-Targeted Chimeric antigen receptor modified T-cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"3","key":"10.1016\/j.intimp.2024.112043_b0415","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jtct.2020.10.002","article-title":"Late effects after Chimeric antigen receptor T cell therapy for lymphoid malignancies","volume":"27","author":"Chakraborty","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0420","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0425","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1182\/hematology.2023000508","article-title":"Bispecific antibody therapies","volume":"2023","author":"de Assis","year":"2023","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.intimp.2024.112043_b0430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12935-023-03045-y","article-title":"Safety and efficacy of T-cell-redirecting bispecific antibodies for patients with multiple myeloma: a systematic review and meta-analysis","volume":"23","author":"Noori","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.intimp.2024.112043_b0435","doi-asserted-by":"crossref","unstructured":"N. Raje et al., \u201cMonitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel,\u201d Blood Cancer Journal 2023 13:1, vol. 13, no. 1, pp. 1\u201317, Aug. 2023, doi: 10.1038\/s41408-023-00879-7.","DOI":"10.1038\/s41408-023-00879-7"},{"issue":"10","key":"10.1016\/j.intimp.2024.112043_b0440","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/d41573-023-00140-7","article-title":"The next-generation CAR-T therapy landscape","volume":"22","author":"Verma","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.intimp.2024.112043_b0445","doi-asserted-by":"crossref","unstructured":"A. Ahmad, \u201cCAR-T Cell Therapy,\u201d International Journal of Molecular Sciences 2020, Vol. 21, Page 4303, vol. 21, no. 12, p. 4303, Jun. 2020, doi: 10.3390\/IJMS21124303.","DOI":"10.3390\/ijms21124303"},{"key":"10.1016\/j.intimp.2024.112043_b0450","article-title":"Clinical investigations of CAR-T cell therapy for solid tumors","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2024.112043_b0455","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2024.112043_b0460","article-title":"Bispecific antibodies: from research to clinical application","volume":"12","author":"Ma","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2024.112043_b0465","doi-asserted-by":"crossref","unstructured":"N. Gera, \u201cThe evolution of bispecific antibodies The evolution of bispecific antibodies,\u201d 2022, doi: 10.1080\/14712598.2022.2040987.","DOI":"10.1080\/14712598.2022.2040987"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924005617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924005617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,27]],"date-time":"2024-12-27T09:02:15Z","timestamp":1735290135000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924005617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":93,"alternative-id":["S1567576924005617"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112043","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current status of bispecific antibodies and CAR-T therapies in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112043"}}